Intervention: DIMETHYL SULFOXIDE
Trial phase: Phase 3
ATC code: G04BX13 | M02AX03
SMILES: CS(C)=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution, 50 cubic centimeters

DMSO Instillation: DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
Eligibility criteria:
Inclusion Criteria:

Female patient aged 18 years or older
No evidence of stress urinary incontinence on physical examination or urodynamics
Patients who have failed prior drug therapy for overactive bladder or detrusor hyperreflexia
Patients with symptoms and signs of OAB, detrusor hyperreflexia, urinary urgency, urinary urge incontinence.
Patient who is mentally competent with the ability to understand and comply with the requirements of the study
Patient who agrees to be available for the follow-up evaluations as required by the protocol
Patient who has given signed informed consent

Exclusion Criteria:

Patient with Post-Void Residual Urine (PVRU) greater than 100 ml on repeated measures. (Patient with a single PVRU of >100 ml and followed by two consecutive PVRU measurements of <100 ml may be included in the study)
Patient with greater than vesicoureteral reflux grade 1, interstitial cystitis, genitourinary fistulae
Patient with pelvic organ prolapse stage III or IV, i.e. the most distal part of the prolapse protruding more than 1 cm beyond the hymen (>+1), at straining
Patient with un-investigated hematuria
Patient with lower tract genitourinary malignancies
Patient on current medication for stress urinary incontinence, such as alpha-adrenergic agonists or duloxetine, within three weeks prior to completing the baseline Bladder Diary (estrogen therapy on a stable dose for at least two months prior to study start is allowed)
Patient with ongoing complications of prior anti-incontinence surgery
Patient who is pregnant, lactating, or planning to become pregnant within the study period
Patient who has received pelvic radiation
Patient with any condition, which could lead to significant postoperative complications, including current infection and uncontrolled diabetes.
Patient who is morbidly obese (defined as BMI > 40 Kg/m2)
Patient who is bedridden, institutionalized or in such physical condition that she cannot move to the closest bathroom without assistance from another person
Patient with current or acute urinary tract infection, including cystitis or urethritis. (Patient with such infections should be treated with antibiotics, with subsequent urinalysis tests confirming the absence of such infection before study inclusion)
Patient with any condition that would preclude treatment due to contraindications and/or warnings in the study product's labeling
Patient on immunomodulatory therapy (suppressive or stimulatory)
Patient with known lidocaine hypersensitivity or hypersensitivity to any anesthetics to be used during the treatment session/surgical procedure
Patient with a concurrent use of another study product within two weeks prior to study start, or who concurrently participate in any other clinical study
Any disease that in the opinion of the Investigator would make the patient unsuitable for the study
Patient with a life expectancy of less than 12 months